{ }
001122334455554433221100
001122334455554433221100

Swiss stock market declines amid trade tensions and corporate earnings reports

The Swiss stock market closed lower, impacted by US tariffs on cars and parts, with the SMI falling 0.7% to 12,867 points. UBS shares plummeted 4.1% after a downgrade by Bank of America, while Roche and other companies also faced losses. In contrast, Nestlé and Alcon saw gains due to positive developments in their business sectors.

Swiss stock market declines amid US tariff concerns and weak bank performance

The Swiss stock market closed lower, impacted by US tariffs on cars and parts, with the SMI falling 0.7% to 12,867 points. UBS shares plummeted 4.1% after a downgrade by Bank of America, while Roche and other companies also faced losses. In contrast, Nestlé and Alcon saw positive movements due to business developments.

swiss stock exchange declines as investors react to economic uncertainties

The Swiss stock exchange closed lower, with the SMI down 0.26% at 11,384.92 points, marking a 3% loss over the week and reducing year-to-date gains to just 2%. Investor uncertainty stems from the Federal Reserve's cautious approach to interest rate cuts and concerns over a potential U.S. government shutdown. Notable declines were seen in UBS, Partners Group, and various insurance companies, while Idorsia plummeted 50.35% due to delays in drug negotiations.

Swiss stock exchange opens lower amid market volatility and interest rate concerns

The Swiss stock exchange opened lower, with the SMI Index down 1.07% at 11,293.27 points, influenced by Wall Street's weak close and Asian market performance. Investors are reacting to the Federal Reserve's cautious stance on interest rate cuts, while today's "witch's day" may lead to increased volatility in trading. Notable declines include UBS (-1.54%) amid the Credit Suisse report, and Logitech (-1.59%), while Richemont fared better with a smaller drop of -0.56%.

bitcoin price plummets amid interest rate concerns and market uncertainty

Bitcoin's price dropped to $92,118, marking its lowest since early December, following a record high of $108,364 earlier in the week. The decline is attributed to investor concerns over inflation and interest rate signals from the US Federal Reserve, prompting a shift towards safer investments. Meanwhile, the Swiss bond market remains stable as traders prepare for the new year, with minimal activity noted ahead of key US economic data releases.

SPI Experiences Afternoon Decline Amid Weak Trading Conditions

The SPI index fell by 0.22% to 15,567.40 points on Friday, with a market capitalization of €2.094 trillion. It has decreased by 0.336% this week and is down from 16,096.21 points a month ago, though it has risen 6.85% since the start of the year. Top performers include Pierer Mobility (+21.49%) and Banque Cantonale du Jura (+4.85%), while Peach Property Group saw the largest decline at -33.41%.
17:38 11.12.2024

equities remain attractive as interest rates are expected to decline

In 2025, equities are expected to dominate investment strategies as falling interest rates diminish the appeal of bonds, according to St. Galler Kantonalbank. With a projected GDP growth of 2.3% in the USA and 1.5% in Switzerland, the focus will be on dividend stocks, which are anticipated to yield around 3%. Meanwhile, cryptocurrencies like Bitcoin are gaining interest but remain highly volatile and speculative.
12:15 28.11.2024

Idorsia announces job cuts and potential deal for blood pressure drug

Idorsia is cutting up to 270 jobs globally, primarily in research and development, as part of cost-saving measures amid ongoing financial struggles. The Basel-based pharmaceutical company has also entered exclusive negotiations for worldwide rights to its blood pressure drug Aprocitentan, expected to yield $35 million. Following the announcement, Idorsia's stock rose by 7%, although it remains down 64% since January, currently valued at CHF 0.81.

Idorsia faces financial struggles as share price declines ahead of report

Idorsia's share price dropped 2.64% to EUR 1.604 on October 2, 2024, amid ongoing financial difficulties, including a negative price/earnings ratio of -0.93 and a net loss of EUR 300 million last year. With a market capitalization of EUR 303.2 million, investor concerns are mounting as they await the quarterly report on October 20, which may provide insights into the company's four drug candidates in clinical phase 3.

Idorsia faces financial hurdles despite recent drug approval successes

Idorsia, the Swiss biotech firm, faces significant financial challenges despite recent progress in product development, with its share price plummeting 36.94% to EUR 1.426. However, the company has received US approval for the antihypertensive drug aprocitentan and presented new data on the sleep aid daridorexant, which could enhance sales in the medium term. Investors are keenly observing the upcoming weeks to see if Idorsia can stabilize its finances while capitalizing on its growth potential.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.